← Leaderboards
Laurent Calvier
Reelin Therapeutics, Inc.
$252,254
Attributed
$756,761
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $260K · FY2023–25$500K$375K$250K$125K$0
'23
'24
'25
Funding mix
By agency
NIH$756,761 · 2
By mechanism
R43$498,548 · 1
R41$258,213 · 1
Top collaborators
- Joachim J Herz3 shared
- Maria Z Kounnas3 shared
Most similar at Reelin Therapeutics, Inc.
Same institution · by research overlap
- Maria Z Kounnas$752,270
Others in their field
Other Rising Stars on “Alzheimer&Apos”
- Kjetil Bjornevik · Harvard University D/B/A Harvard School Of Public Health$3,280,861
- Yanling Wang · Rush University Medical Center$2,986,919
- William G Mantyh · University Of Minnesota$2,961,521
- Allison Mercedes Caban-Holt · University Of Miami School Of Medicine$2,611,182
- Brian Stephen Appleby · Cleveland Clinic Lerner Com-Cwru$2,482,260
- Noah Ray Johnson · University Of Colorado Denver$2,282,487
Research focus
Alzheimer&AposFutureLeadAmyloidBrainDementiaS DiseasePreventBindingCellsSenile PlaquesPathologySiteAmyotrophic Lateral SclerosisAmyloid Beta-Protein PrecursorChronicAdhesionsCopy Number PolymorphismDab2 GeneAffinityAstrocytesCell PhysiologyBiologicalCell Type
Grant awards (3)
Identification of next generation gamma-secretase modulators for Alzheimer's disease$258,213
R41 · FY2025 · AG
Effect of APP copy number variants in Alzheimer's disease and and Down Syndrome on Reelin expression and function$238,549
R43 · FY2024 · AG
Effect of APP copy number variants in Alzheimer's disease and and Down Syndrome on Reelin expression and function$259,999
R43 · FY2023 · AG